Varex Imaging Corporation (VREX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: strong financial performance with record high revenue and improved profitability, but concerns about cash reduction and uncertain guidance. The Q&A indicates solid demand and growth prospects, but management's lack of specific guidance and avoidance of details raises uncertainty. Without clear guidance, the market may react cautiously, resulting in a neutral stock price movement.
Key Financial Performance
Fourth Quarter Revenue $229 million, up 11% year-over-year, driven by strong demand from global CT customers and strength in the Industrial segment.
Industrial Segment Revenue (Q4) $77 million, the highest revenue quarter ever for this segment, up 25% year-over-year, driven by demand for security inspection systems and components.
Medical Segment Revenue (Q4) $152 million, up 5% year-over-year, led by global sales of CT tubes and strong performance in fluoroscopy and radiography.
Non-GAAP Gross Margin (Q4) 34%, up 130 basis points year-over-year, benefiting from higher volume and favorable product sales mix.
Non-GAAP Earnings Per Share (Q4) $0.37, up $0.21 compared to last year, reflecting improved operational performance.
Full Fiscal Year Revenue $845 million, up 4% year-over-year, with Medical revenue at $593 million (up 2%) and Industrial revenue at $252 million (up 10%).
Non-GAAP Gross Margin (Full Year) 35%, up 230 basis points year-over-year, driven by operational improvements and favorable sales mix.
Non-GAAP EBITDA (Full Year) $122 million, up $33 million from $89 million last year, reflecting strong financial performance.
Non-GAAP Earnings Per Share (Full Year) $0.90, up $0.35 year-over-year, indicating improved profitability.
Cash, Cash Equivalents, and Marketable Securities (End of Year) $155 million, down from $213 million last year, primarily due to $75 million used to retire convertible debt.
Operating Income (Q4) $20 million, an increase of $9 million compared to the previous year, with an operating margin of 10% of revenue.
Net Income (Q4) $12 million, with GAAP EPS of $0.29 per share, reflecting improved financial results.
Adjusted EBITDA (Q4) $35 million, representing 15% of sales, showcasing strong quarterly performance.
R&D Spending (Q4) $24 million, up $2 million year-over-year, representing 10% of revenues, driven by investments in growth initiatives.
SG&A Expense (Full Year) $122 million, down $1 million year-over-year, representing 14% of revenues, indicating cost management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Photon Counting for CT: Introduced innovative photon counting technology for CT, collaborating with OEM customers and the Technical University of Munich to advance product development.
Radiographic Detector for Value Segment: Launched a radiographic detector from a new facility in India, targeting the value segment.
Cargo Systems in Industrial: Developed and shipped over 15 cargo inspection systems to countries like Mexico, Iraq, Brazil, and Saudi Arabia, with $55 million in orders booked.
Geographic Expansion: Expanded sales in regions like India, South Asia, the Middle East, and Latin America, focusing on value and mid-tier products for radiographic and CT systems.
China Market Recovery: Observed increased tender activity in China, driven by rural healthcare expansion plans and demand for value and mid-tier CT systems.
India Facility Expansion: Completed the first stage of India expansion plans, ramping up production of radiographic detectors and enabling vertical integration for cost reduction.
Supply Chain Regionalization: Strengthened geopolitical resiliency through regionalized supply chains and export-oriented manufacturing.
Photon Counting CT Demonstrator: Collaborated with the Technical University of Munich to develop a photon counting CT system demonstrator, showcasing its value proposition at trade shows in 2026.
Nanotube-Based Coal Emitters: Invested in nanotube-based coal emitters for next-generation X-ray sources, collaborating with OEMs to develop novel applications.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Global Tariff Challenges: The company faced a challenging start to fiscal 2025 due to unpredictable global tariff situations, which impacted customer ordering patterns. Although the situation stabilized, it remains a potential risk for future operations.
China Market Uncertainty: Uncertainty around the implementation of stimulus programs in China led to delays in imaging equipment purchases. While this appears to be resolved, it highlights the risk of dependency on specific markets.
Supply Chain and Manufacturing Regionalization: The company is intensifying efforts to strengthen geopolitical resiliency through supply chain and manufacturing regionalization. This indicates potential risks related to supply chain disruptions and trade challenges.
Debt Levels: The company used $75 million to retire convertible debt, reducing cash reserves from $213 million to $155 million. This could limit financial flexibility for future investments or operations.
Photon Counting CT Development: While progress has been made, the adoption of photon counting CT technology is still in early stages and depends on securing additional OEM design-ins, which poses a strategic execution risk.
Nanotube-Based Coal Emitters: The development of nanotube-based coal emitters is in collaboration with OEMs, but bringing applications to market takes time, posing a risk of delayed returns on investment.
Industrial Segment Scaling: Scaling up production capacity for cargo systems in fiscal 2026 involves operational risks, including meeting demand and maintaining quality standards.
R&D Investment: Increased R&D spending, particularly in growth initiatives like photon counting and security systems, represents a financial risk if these investments do not yield expected returns.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Revenues for the first quarter of fiscal 2026 are expected to be between $200 million and $215 million.
Earnings Per Share (EPS): Non-GAAP earnings per diluted share for the first quarter of fiscal 2026 are expected to range between $0.05 and $0.25.
Gross Margin: Non-GAAP gross margin for the first quarter of fiscal 2026 is projected to be between 32% and 34%.
Operating Expenses: Non-GAAP operating expenses for the first quarter of fiscal 2026 are expected to be approximately $52 million.
Tax Rate: The tax rate for the first quarter of fiscal 2026 is expected to be about 23%.
Photon Counting CT: Plans to showcase a photon counting CT system at major trade shows in 2026, aiming to demonstrate its value proposition beyond higher resolution images, including precise material discrimination and improved workflow.
India Expansion: The detectors factory in Vizag, India is ramping up production of radiographic detectors, with plans for further vertical integration to support cost-reduction efforts.
Cargo Systems: Scaling up production capacity of cargo systems in fiscal 2026, including implementing a rail cargo scanner in Latin America and leveraging strong customer relationships for upcoming tenders.
Nanotube Technology: Continued investment in nanotube-based coal emitters, with plans to provide more visibility to this technology at trade shows in fiscal 2026.
China Market Recovery: Customers in China are projecting stronger orders and sales for 2026 compared to 2024 and 2025, driven by increased tender activity for value and mid-tier CT systems to support rural healthcare expansion plans.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What percentage of sales came from the top 10 customers, and can it be split between Medical and Industrial?
A:The top 10 customers accounted for 52% of sales, which is consistent with the historical range of 50%-55%. The company does not break this down between Medical and Industrial because the majority are Medical customers, and disclosing this could reveal sensitive information about individual customers.
Q:Is there a structural shift in the Medical and Industrial segments, and what systemic forces could change in 2026?
A:Industrial sales have been growing as a percentage of overall sales, approaching 30% and expected to reach mid-30s. Medical sales show volatility due to geopolitical factors, with non-Chinese OEMs increasingly requesting shipments from Chinese facilities. No significant structural shift was identified.
Q:What are the implications of GE and Siemens Healthineers potentially divesting their China businesses for Varex?
A:There are no significant implications for Varex as most of its China business comes from Chinese OEMs. Non-Chinese OEMs do some business in China, but the impact is expected to be minimal. Chinese OEMs are also expanding commercially outside of China.
Q:Can any insights from Q1 be applied to the full year outlook?
A:The demand environment is solid, with expected growth in both Medical and Industrial segments. Medical business ex-China is expected to grow, while China is modeled as stable. Q1 and Q3 have easier comparisons, while Q2 and Q4 are more challenging. Gradual growth is expected throughout the year.
Q:What is the outlook for China and its impact on the business?
A:China is expected to remain stable to slightly grow, but modeling is challenging due to changing global supply chains. Tariffs and U.S.-China uncertainties are factored into the stable outlook.
Q:What drove the strong Industrial gross margins in the quarter?
A:Higher-than-usual service revenues from the linacs installed base, which have higher margins than hardware, contributed to the strong Industrial gross margins. This is considered unusual and not the norm.
Q:Was there anything unusual about the strong Q4 revenue performance?
A:No significant unusual factors were identified. Strong demand in both segments and shipments of high-value cargo systems contributed to the performance.
Q:What is the status of the India operations and its impact on gross margins?
A:Detector shipments from India have started and are expected to ramp up in FY '26. The tubes factory is 12-15 months away from production. India operations are expected to improve gross margins for legacy products but have a limited overall impact due to the small revenue proportion.
Q:What is the outlook for R&D expenses?
A:R&D expenses can fluctuate due to project timing and material costs. Overall, operating expenses are planned to be lower in the coming fiscal year, around $52-$53 million per quarter.
Q:What is the growth outlook for cargo systems in 2026?
A:Growth is expected in cargo systems, with new products like VXM-6 mobile cargo inspection systems and rail cargo scanners contributing. Specific order sizes and timelines were not disclosed.
Q:What is the impact of tariffs on gross margins?
A:Tariffs impact gross margins by 100-150 basis points. Efforts to reroute supply chains and the upcoming India tubes factory may mitigate some of this impact in the future.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the size and timeline of cargo system orders, as well as the exact breakdown of Medical versus Industrial sales within the top 10 customers. Additionally, they did not provide annual guidance, citing various reasons, and used general terms like 'solid demand' and 'gradual growth' without offering precise data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APAC Sales
APAC recovery
Americas EMEA
Arabia sale
Brazil Saudi
CT strength
China revenue
Conference today
EMEA APAC
India cargo
Industrial cargo
Industrial photon
Iraq Brazil
Medical SGA
Medical increase
Non margin
OEM
Revenues
SGA expense
basis share
cargo system
facility
income increase
income share
increase margin
increase revenue
introduction
margin improvement
market
photon CT
photon counting
point share
product sale
revenue increase
sale security
segment demand
share result
shipment
strength segment
system Industrial
volume product
VREX Transcript
Varex Imaging Corporation (VREX) Q2 2026 Earnings Call Transcript
Positive5-7
The earnings call showed strong financial performance with a 5% revenue increase and improved gross margins. EPS also grew to $0.50, indicating robust profitability. The medical imaging segment's demand supports future growth. Although operating expenses rose, they were tied to R&D investments, which could drive innovation. No strategic initiatives or risks were discussed, leaving a neutral impact. Overall, the financial results and EPS improvement suggest a positive stock price movement.
Varex Imaging Corporation (VREX) Q1 2026 Earnings Call Transcript
Positive2-11
The earnings call summary reveals strong financial performance with increased operating income and adjusted EBITDA. The Q&A section highlights optimism in the market outlook and potential double-digit growth in the Industrial segment. The India expansion and photon counting technology are promising, despite some inventory challenges. The cautious EPS guidance is offset by strong CT adoption and customer engagement. Overall, the sentiment is positive, likely resulting in a 2% to 8% stock price increase.
Varex Imaging Corporation (VREX) Q4 2025 Earnings Call Transcript
Unknown11-18
The earnings call presents a mixed picture: strong financial performance with record high revenue and improved profitability, but concerns about cash reduction and uncertain guidance. The Q&A indicates solid demand and growth prospects, but management's lack of specific guidance and avoidance of details raises uncertainty. Without clear guidance, the market may react cautiously, resulting in a neutral stock price movement.
Varex Imaging Corporation (VREX) Q3 2025 Earnings Call Transcript
Unknown8-8
The earnings call summary presents a mixed picture. Financial performance is stable with strong cash management and expected revenue growth, but gross margins are impacted by tariffs. Product development in photon counting is promising but lacks immediate commercialization. Market strategy shows steady demand in China and a strong cargo systems pipeline, but lacks clarity in future guidance. Shareholder returns and debt repayment plans are positive, yet overall, the lack of clear guidance and tariff impacts balance the sentiment to neutral.
VREX Slides
VREX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
